- Home
- COYA vs FATE Comparison
COYA vs FATE Comparison
Compare COYA & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | FATE |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 139.6M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | COYA | FATE |
|---|---|---|
| Price | $4.47 | $1.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $15.80 | $4.10 |
| AVG Volume (30 Days) | 101.5K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | $3,554,061.00 | ★ $6,646,000.00 |
| Revenue This Year | $69.95 | N/A |
| Revenue Next Year | N/A | $1.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.94 | $0.66 |
| 52 Week High | $7.75 | $1.94 |
Technical Indicators
Market Signals| Indicator | COYA | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 40.53 |
| Support Level | $4.50 | $0.96 |
| Resistance Level | $5.21 | $1.16 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 22.00 | 7.69 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.